KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.

Mariano Provencio, David Aguiar, Mónica Antoñanzas, M Carmen Areses, Aitor Azkárate, Andrés Barba, Reyes Bernabé, Remei Blanco, Miguel Borregón, Begoña Campos, Juan Coves, Javier de Castro, Marta Domènech, Manuel Dómine, Rosario García Campelo, Clara Lucía-Gozálvez, Martín Lázaro-Quintela, Amelia Insa, Óscar Juan-Vidal, Rafael López Castro, Alex Martínez-Marti, Soledad Medina, M Ángeles Moreno, Ernest Nadal, Alejandro Olivares-Hernández, Noemí Reguart, M Ángeles Sala, Karla Medina, Laia Vila, Bartomeu Massutí

Expert Opin Biol Ther 26(5) 441-449

PMID42159280
PMCID-
DOI10.1080/14712598.2026.2677905
发表日期2026-05-20
摘要

摘要

Lung cancer remains the leading cause of cancer-related deaths worldwide. Despite advances to improve treatment in resectable early-stage and locally advanced non-small cell lung cancer (NSCLC), survival rates after 5 years remain low, with a high risk of disease progression. Patients who fail to achieve a pathological complete response (pCR) after neoadjuvant treatment have unfavorable outcomes. ARIAN is a phase III, multicenter, open-label, randomized trial evaluating adjuvant treatment in adults with stage IB-IIIB (N2) NSCLC who have undergone neoadjuvant chemo-immunotherapy but did not achieve pCR after completing surgical resection. Patients will be stratified based on programmed death receptor-ligand 1 (PD-L1) tumor expression and randomized (1:1:1) to observation for 10 months (Arm 1), zimberelimab for 13 cycles (Arm 2), or sacituzumab govitecan and zimberelimab for 8 cycles followed by zimberelimab monotherapy for 5 cycles (Arm 3). The primary endpoint is disease-free survival, and secondary endpoints include overall survival and safety.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。